【NishithDesai】印度制药工业-监管、法律和税务概述-2024.8

Summary of The Indian Pharmaceutical Industry: Regulatory, Legal and Tax Overview

Core Content

The Indian pharmaceutical industry is experiencing rapid growth and is becoming a key player in the global market. With a projected value of USD 130 billion by the end of 2030, the sector is attracting significant foreign direct investment (FDI), collaborations, and mergers and acquisitions (M&A) activity. The industry is characterized by its focus on generic medicines, branded generics, innovator medicines, and the production of active pharmaceutical ingredients (APIs). India's regulatory and legal environment has evolved to support innovation and compliance with international standards, particularly after its accession to the WTO's TRIPS agreement in 2005.

Main Points

Industry Growth and Trends

• Projected Growth: The industry is expected to reach USD 130 billion by 2030.
• Domestic Growth: The domestic market grew by 6.8% in 2023.
• Export Growth: India's drug and pharmaceutical exports increased by 9.67% in FY 2023-24 to USD 27.9 billion.
• Clinical Trials: India is becoming a preferred site for global clinical trials, with the market expected to reach USD 3.15 billion by 2025.
• Collaborations: There is a rising trend of collaborations with global pharmaceutical companies, including co-development and joint ventures.

Investment Climate

• FDI in Pharmaceuticals: FDI is allowed up to 100% in the pharmaceutical sector through the automatic route.
• Brownfield Projects: Up to 74% FDI is permitted through the automatic route for brownfield projects, with approval required beyond that.
• Negative List: Some sectors are subject to the negative list, requiring prior approval for FDI.
• Unincorporated Entities: Options include Liaison Office, Branch Office, and Project Office, each with specific restrictions and purposes.

Legal and Regulatory Framework

• Key Laws:

  • Drugs and Cosmetics Act, 1940
  • Drugs and Cosmetics Rules, 1945
  • New Drugs and Clinical Trial Rules, 2019
  • Essential Commodities Act, 1955
  • Drugs (Price Control) Order, 2013
  • Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
  • Narcotic Drugs and Psychotropic Substances Act, 1985
  • Patents Act, 1970
  • Trade Marks Act, 1999
  • Competition Act, 2002

• Regulatory Bodies:

  • CDSCO (Central Drugs Standard Control Organization) under the DCGI (Drug Controller General of India) is responsible for product approval, standards, and clinical trials.
  • State Governments handle approvals for manufacturing and selling drugs.

Intellectual Property (IP) Protection

• Patent Law: India now provides 20 years of patent protection for pharmaceutical products.
• Patent Types: India recognizes both product and process patents.
• IP Protection for Innovation: The legal framework supports the protection of pharmaceutical products developed through innovative processes such as 3D printing.
• Trademarks: International trademarks can be protected through judicial decisions even without registration in India.

Tax Regime

• Direct Taxes: Governed by the Income Tax Act, 1961, and Goods and Services Tax (GST) rules.
• Indirect Taxes: Includes customs duties and other indirect taxes.
• Tax Treaties: India has treaties with favorable jurisdictions such as Mauritius, Singapore, and the Netherlands.

Anti-Corruption and Corporate Governance

• PCA (Prevention of Corruption Act, 1988): The primary anti-corruption law in India, covering public servants and commercial organizations.
• Key Provisions:
  • Criminalizes offering and receiving undue advantage to public servants.
  • Broad definition of 'public servant' includes individuals and organizations performing public duties.
  • Does not criminalize facilitation payments or private sector corruption.
• Corporate Governance: Companies are encouraged to implement and regularly review anti-corruption policies and employee training.

Key Issues and Challenges

• Promotion and Advertisement: Regulations on advertising and promotion of pharmaceutical products are stringent.
• Price Control: The Drug Price Control Order (DPCO) 2013 regulates pricing of essential drugs.
• Labeling: Must comply with strict labeling regulations.
• GMP Compliance: Good Manufacturing Practices (GMP) are essential for quality assurance.
• Environmental Concerns: Companies must adhere to environmental diligence requirements.
• Fixed Dose Combinations (FDCs): These are subject to regulatory scrutiny.
• Overlap with Other Industries: The sector overlaps with bio-pharma and med-tech, requiring careful legal structuring.

Conclusion

The Indian pharmaceutical industry is poised for continued growth, supported by a robust legal and regulatory framework, favorable tax policies, and a conducive investment climate. The sector is becoming increasingly attractive for global players due to its low-cost production, skilled workforce, and increasing focus on innovation and research. As the industry evolves, it is crucial for companies to navigate the complex legal and regulatory landscape effectively to ensure compliance and sustainable growth.